These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 15650765

  • 1. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
    Barzon L, Gnatta E, Castagliuolo I, Trevisan M, Moretti F, Pontecorvi A, Boscaro M, Palù G.
    Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
    [Abstract] [Full Text] [Related]

  • 2. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.
    Shimura H, Suzuki H, Miyazaki A, Furuya F, Ohta K, Haraguchi K, Endo T, Onaya T.
    Cancer Res; 2001 May 01; 61(9):3640-6. PubMed ID: 11325833
    [Abstract] [Full Text] [Related]

  • 3. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
    Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A.
    Oncogene; 1997 Feb 13; 14(6):729-40. PubMed ID: 9038381
    [Abstract] [Full Text] [Related]

  • 4. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
    Takeda T, Yamazaki M, Minemura K, Imai Y, Inaba H, Suzuki S, Miyamoto T, Ichikawa K, Kakizawa T, Mori J, DeGroot LJ, Hashizume K.
    Cancer Gene Ther; 2002 Oct 13; 9(10):864-74. PubMed ID: 12224028
    [Abstract] [Full Text] [Related]

  • 5. Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer.
    Barzon L, Bonaguro R, Castagliuolo I, Chilosi M, Gnatta E, Parolin C, Boscaro M, Palù G.
    J Clin Endocrinol Metab; 2002 Nov 13; 87(11):5304-11. PubMed ID: 12414907
    [Abstract] [Full Text] [Related]

  • 6. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
    Bravo SB, García-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, López-Lázaro L, Zalvide J, Barreiro F, Pombo CM, Alvarez CV.
    Clin Cancer Res; 2005 Nov 01; 11(21):7664-73. PubMed ID: 16278386
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma.
    Shi Y, Zou M, Baitei EY, Alzahrani AS, Parhar RS, Al-Makhalafi Z, Al-Mohanna FA.
    Cancer Gene Ther; 2008 Feb 01; 15(2):101-7. PubMed ID: 18197164
    [Abstract] [Full Text] [Related]

  • 8. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system.
    Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, Niwa M.
    Cancer Res; 1999 Jul 01; 59(13):3049-52. PubMed ID: 10397242
    [Abstract] [Full Text] [Related]

  • 9. pCLPG: a p53-driven retroviral system.
    Strauss BE, Costanzi-Strauss E.
    Virology; 2004 Apr 10; 321(2):165-72. PubMed ID: 15051377
    [Abstract] [Full Text] [Related]

  • 10. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
    Emiliusen L, Gough M, Bateman A, Ahmed A, Voellmy R, Chester J, Diaz RM, Harrington K, Vile R.
    Gene Ther; 2001 Jul 10; 8(13):987-98. PubMed ID: 11438833
    [Abstract] [Full Text] [Related]

  • 11. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
    Tabotta W, Klein D, Hohenadl C, Salmons B, Günzburg WH.
    J Gene Med; 2001 Jul 10; 3(5):418-26. PubMed ID: 11601755
    [Abstract] [Full Text] [Related]

  • 12. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
    Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC.
    J Nucl Med; 2007 Sep 10; 48(9):1553-61. PubMed ID: 17704247
    [Abstract] [Full Text] [Related]

  • 13. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter.
    Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M, Yamashita S.
    Endocrinology; 1998 Sep 10; 139(9):3996-9. PubMed ID: 9724055
    [Abstract] [Full Text] [Related]

  • 14. Restoration of p53 function in anaplastic Wilms' tumor.
    Delatte SJ, Hazen-Martin DJ, Re GG, Kelly JR, Sutphin A, Tagge EP.
    J Pediatr Surg; 2001 Jan 10; 36(1):43-50. PubMed ID: 11150436
    [Abstract] [Full Text] [Related]

  • 15. Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.
    Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, Miyauchi A.
    Oncol Rep; 2007 Sep 10; 18(3):715-20. PubMed ID: 17671725
    [Abstract] [Full Text] [Related]

  • 16. Combined RNA interference of hexokinase II and (131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma.
    Kim JE, Ahn BC, Hwang MH, Jeon YH, Jeong SY, Lee SW, Lee J.
    J Nucl Med; 2011 Nov 10; 52(11):1756-63. PubMed ID: 21994409
    [Abstract] [Full Text] [Related]

  • 17. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors.
    Jiang S, Altmann A, Grimm D, Kleinschmidt JA, Schilling T, Germann C, Haberkorn U.
    Cancer Gene Ther; 2001 Jul 10; 8(7):469-72. PubMed ID: 11498767
    [Abstract] [Full Text] [Related]

  • 18. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
    Kitazono M, Chuman Y, Aikou T, Fojo T.
    J Clin Endocrinol Metab; 2001 Feb 10; 86(2):834-40. PubMed ID: 11158054
    [Abstract] [Full Text] [Related]

  • 19. [Construction of the wt-p53 gene recombinant retroviral vector. Inhibiting the growth of laryngocarcinoma cell line].
    Chen X, Cao K, Liu D, Wang Z, Liang C.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1996 Aug 10; 18(4):252-6. PubMed ID: 9388972
    [Abstract] [Full Text] [Related]

  • 20. Cell-type- and promoter-dependent ts phenotype of p53 Val135.
    Sehgal PB, Margulies L.
    Oncogene; 1993 Dec 10; 8(12):3417-9. PubMed ID: 8247545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.